Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Assets Average (2016 - 2025)

Historic Assets Average for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $812.7 million.

  • Corcept Therapeutics' Assets Average rose 844.12% to $812.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $812.7 million, marking a year-over-year increase of 844.12%. This contributed to the annual value of $731.0 million for FY2024, which is 2133.89% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Assets Average is $812.7 million, which was up 844.12% from $824.1 million recorded in Q2 2025.
  • Corcept Therapeutics' Assets Average's 5-year high stood at $843.5 million during Q1 2025, with a 5-year trough of $445.9 million in Q1 2022.
  • Its 5-year average for Assets Average is $626.9 million, with a median of $576.9 million in 2021.
  • As far as peak fluctuations go, Corcept Therapeutics' Assets Average crashed by 2066.04% in 2022, and later surged by 3469.07% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Assets Average stood at $504.6 million in 2021, then grew by 10.66% to $558.3 million in 2022, then grew by 8.85% to $607.8 million in 2023, then soared by 33.67% to $812.4 million in 2024, then rose by 0.03% to $812.7 million in 2025.
  • Its Assets Average stands at $812.7 million for Q3 2025, versus $824.1 million for Q2 2025 and $843.5 million for Q1 2025.